retatrutide triple agonist glp-1 gip glucagon phase 2 obesity trial hormone receptor clinical results Retatrutide (Triple-Action Jab): III Triple G Agonists – Retatrutide.

Another 2025 article demonstrated that GLP-1 agonists were associated with development of NAION among Medicare enrollees

(8) The base-case scenario assumed constant mortality rates

Purinergic control of vascular tone in the retina

47 There was less incidence of nausea for exenatide once weekly than with twice-daily exenatide or liraglutide

There is insufficient evidence to recommend allulose as a therapeutic intervention for glycemic control, and it should not replace prescribed medications or established dietary management strategies

In a randomized, placebo-controlled trial of semaglutide treatment, 62 % of adolescent participants in the semaglutide group achieved a loss of body weight of at least 10 %, with 37 % of subjects achieving weight reduction of at least 20 % [138,156]